Research Article
Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role?
Table 1
Demographic data based on the presence of high liver stiffness measurement (LSM > 7 kPa).
| | | All patients | LSM ≤ 7 kPa | LSM > 7 kPa | | | | () | () | () |
| | Age (years)† | 49.2 ± 14.0 | 48.7 ± 14.1 | 53.4 ± 12.7 | 0.182 | | Male ‡ | 75 (45.5) | 65 (44.2) | 10 (55.6) | 0.454 | | Body mass index (kg/m2)† | 24.8 ± 4.7 | 24.0 ± 4.0 | 30.77 ± 5.7 | <0.0001 | | Waist circumference (cm)† | 87.0 ± 12.3 | 85.0 ± 10.7 | 104.1 ± 12.0 | <0.0001 | | Diabetes mellitus ‡ | 31 (18.8) | 22 (15) | 9 (50) | 0.001 | | Hypertension ‡ | 55 (33.3) | 43 (29.3) | 12 (66.7) | 0.003 | | Dyslipidemia ‡ | 88 (53.3) | 74 (50.3) | 14 (77.8) | 0.043 | | Metabolic syndrome ‡ | 83 (50.3) | 66 (44.9) | 17 (94.4) | <0.0001 | | Psoriasis disease-related factors | | | | | | Duration of disease (years)† | 16.5 ± 12.1 | 16.7 ± 12.3 | 14.8 ± 10.9 | 0.533 | | PASI score† | 3.0 ± 2.7 | 2.8 ± 2.6 | 4.2 ± 3.2 | 0.042 | | Severe psoriasis‡ | 6 (3.6) | 4 (2.7) | 2 (11.1) | 0.130 | | Psoriatic arthritis ‡ | 35 (21.2) | 29 (19.7) | 6 (33.3) | 0.220 | | Cumulative dose of MTX‡ | | | | | | None | 57 (34.5) | 51 (34.7) | 6 (33.3) | 0.906 | | 1.5 g | 69 (41.8) | 62 (42.2) | 7 (38.9) | | 1.5 g | 39 (23.6) | 34 (23.1) | 5 (27.8) |
|
|
LSM: liver stiffness measurement; PASI: psoriasis area and severity index; and MTX: methotrexate; †mean ± SD; ‡ (%).
|
